REGENXBIO Inc.
RGNX
$9.66
$0.293.10%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 108.02M | 6.39M | 30.34M | 29.73M | 21.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 108.02M | 6.39M | 30.34M | 29.73M | 21.36M |
| Cost of Revenue | 57.13M | 68.41M | 65.54M | 61.83M | 64.71M |
| Gross Profit | 50.89M | -62.02M | -35.20M | -32.09M | -43.35M |
| SG&A Expenses | 21.62M | 21.31M | 22.38M | 20.25M | 19.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 12.00K | 36.00K | 54.00K | 65.00K | 45.00K |
| Total Operating Expenses | 78.76M | 89.76M | 87.97M | 82.14M | 84.64M |
| Operating Income | 29.26M | -83.36M | -57.64M | -52.41M | -63.28M |
| Income Before Tax | 22.71M | -90.05M | -67.15M | -61.94M | -70.87M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 22.71M | -90.05M | -67.15M | -61.94M | -70.87M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.71M | -90.05M | -67.15M | -61.94M | -70.87M |
| EBIT | 29.26M | -83.36M | -57.64M | -52.41M | -63.28M |
| EBITDA | 33.02M | -79.51M | -53.77M | -48.53M | -59.37M |
| EPS Basic | 0.43 | -1.72 | -1.30 | -1.20 | -1.38 |
| Normalized Basic EPS | 0.27 | -1.07 | -0.81 | -0.75 | -0.86 |
| EPS Diluted | 0.43 | -1.72 | -1.30 | -1.20 | -1.38 |
| Normalized Diluted EPS | 0.27 | -1.07 | -0.81 | -0.75 | -0.86 |
| Average Basic Shares Outstanding | 52.82M | 52.43M | 51.75M | 51.69M | 51.48M |
| Average Diluted Shares Outstanding | 53.02M | 52.43M | 51.75M | 51.69M | 51.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |